Third-line Treatment

Third-Line Treatment is a therapeutic intervention employed in the management of metastatic disease after the failure of two prior systemic treatments, distinguished by its sequential positioning in the treatment algorithm and typically reserved for cases with progressive disease or resistance to first- and second-line regimens.

650

Publications

31.4K

Citations

5.4K

Authors

1.8K

Institutions

Publications per year

2017–2026

287

Parents

Metastatic Disease Management

Publications

650

Canadian Network for Mood and Anxiety Treatments (<scp>CANMAT</scp>) and International Society for Bipolar Disorders (<scp>ISBD</scp>) 2018 guidelines for the management of patients with bipolar disorder

Lakshmi N. Yatham, Sidney H. Kennedy, Sagar V. Parikh et al. · Bipolar Disorders · 2018 · 1.8K citations · Full text

Medicine, Pharmacotherapy, Psychiatry +14

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

Thomas Powles, Elizabeth R. Plimack, Denis Soulières et al. · The Lancet Oncology · 2020 · 745 citations

Medicine, Oncology, Pharmacology +13

A Comparison of Lithium and T <sub>3</sub> Augmentation Following Two Failed Medication Treatments for Depression: A STAR*D Report

Andrew A. Nierenberg, Maurizio Fava, Madhukar H. Trivedi et al. · American Journal of Psychiatry · 2006 · 564 citations

Pharmacy, Pharmacotherapy, Psychiatry +16

Pharmacological Management of Chronic Neuropathic Pain: Revised Consensus Statement from the Canadian Pain Society

DE Moulin, AJ Clark, Hance Clarke et al. · Pain Research and Management · 2014 · 529 citations · Full text

Nursing, Pharmacology, Pharmacotherapy +17

Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300

Yu Jeong Bang, Eduardo Yañez Ruiz, Eric Van Cutsem et al. · Annals of Oncology · 2018 · 503 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

1–5 of 650

Authors

5.4K

DS
Daniele Santini
Università Campus Bio-Medico, Italy
8 publications · 760 citations
8
h-index
NB
Narikazu Boku
National Cancer Center Hospital East, Japan
8 publications · 1.1K citations
8
h-index
YC
Ying Cheng
Jilin Province Tumor Hospital, China
7 publications · 666 citations
7
h-index
JH
Jianxing He
Guangzhou Medical University, China
7 publications · 321 citations
7
h-index
BH
Baohui Han
Shanghai Chest Hospital, China
6 publications · 507 citations
6
h-index

1–5 of 5.4K

Institutions

1.8K

1–8 of 1.8K

Venues

PubMed
Repository · 53 publications · 1.3K citations
23
h-index
Journal of Clinical Oncology
33 publications · 2.4K citations
20
h-index
Annals of Oncology
13 publications · 1.7K citations
13
h-index
American Journal of Clinical Oncology
AJCO · 11 publications · 371 citations
11
h-index
Anti-Cancer Drugs
10 publications · 245 citations
10
h-index

1–5